HormonesResearch PaperPaywall

Testosterone Therapy Reshapes Muscle Gene Activity in Klinefelter Syndrome

Single-nucleus RNA sequencing reveals TRT partially reverses fibrotic and inflammatory muscle changes in hypogonadal Klinefelter men.

Thursday, June 18, 2026 1 views
Published in J Clin Endocrinol Metab
A clinical researcher examining a muscle biopsy slide under a fluorescence microscope in a modern genomics laboratory, with colorful cell-type cluster visualizations on a monitor in the background

Summary

Klinefelter syndrome (KS), the most common sex chromosome disorder in men, causes low testosterone and muscle loss. Danish researchers used cutting-edge single-nucleus RNA sequencing to map gene activity across 81,786 individual muscle cell nuclei in four KS patients before and after one year of testosterone replacement therapy (TRT), comparing them to healthy controls. Before treatment, KS muscle showed widespread signs of fibrosis, inflammation, and impaired stem cell function. After TRT, gene expression shifted toward muscle repair, better structural integrity, and improved blood vessel formation. Three of four patients gained muscle mass. However, a persistent inflammatory signature remained even after a year of treatment, suggesting testosterone therapy only partially reverses the deep cellular damage caused by prolonged hypogonadism in this condition.

Detailed Summary

Klinefelter syndrome affects roughly 1 in 600 males and is the leading chromosomal cause of male hypogonadism. Beyond infertility, it drives profound metabolic and body composition changes — most notably reduced skeletal muscle mass — that raise long-term risks for cardiometabolic disease and reduced healthspan. Testosterone replacement therapy is standard care, yet exactly how it reshapes muscle at the cellular level has remained poorly understood.

Researchers at Aarhus University Hospital applied single-nucleus RNA sequencing to vastus lateralis (thigh) muscle biopsies from four KS patients at diagnosis and again after 12 months of TRT, alongside biopsies from four age-matched healthy male controls. This approach captures the transcriptional activity of individual nuclei across all major cell types residing in muscle tissue, providing an unprecedented resolution of biological change.

The study profiled 81,786 nuclei across ten distinct cell types. At baseline, untreated KS muscle displayed pervasive transcriptional reprogramming: elevated fibrotic and adipogenic gene programs, heightened inflammatory signaling, and disrupted progression of muscle stem cells through normal developmental trajectories — a pattern suggesting the tissue was structurally compromised and poorly primed for repair. After one year of TRT, testosterone and gonadotropin levels normalized, and gene expression shifted meaningfully toward pro-regenerative pathways, improved structural integrity, and vascular remodeling. Three of four patients gained measurable muscle mass.

Despite these gains, a substantial KS-specific transcriptional signature persisted post-treatment, most notably chronic inflammatory signaling. This suggests that while TRT is beneficial, it does not fully reverse the cellular consequences of long-standing testosterone deficiency.

For clinicians and longevity-focused individuals, these findings underscore that earlier testosterone intervention in KS — before irreversible fibrotic and inflammatory remodeling sets in — may be critical to preserving muscle healthspan. The study is exploratory given its small sample size, and findings await replication in larger cohorts.

Key Findings

  • TRT normalized testosterone levels and drove muscle mass gains in 3 of 4 KS patients within one year.
  • Untreated KS muscle showed elevated fibrotic, adipogenic, and inflammatory gene programs at the cellular level.
  • Pseudotime analysis revealed disrupted muscle stem cell progression in untreated KS, impairing regenerative capacity.
  • After TRT, gene expression shifted toward structural repair, regeneration, and vascular remodeling.
  • A persistent inflammatory transcriptional signature remained post-TRT, suggesting incomplete reversal of hypogonadal damage.

Methodology

This pilot study used single-nucleus RNA sequencing on vastus lateralis biopsies from 4 KS patients (pre- and post-12-month TRT) and 4 age-matched male controls, profiling 81,786 nuclei across 10 cell types. Pseudotime trajectory analysis was used to assess muscle stem cell developmental progression. The within-patient longitudinal design strengthens causal inference despite the small sample.

Study Limitations

The sample size is very small (n=4 KS patients, n=4 controls), limiting statistical power and generalizability — the authors themselves label this an exploratory pilot study. Summary is based on the abstract only, as the full text is not open access. Longer follow-up studies are needed to determine whether the persistent inflammatory signature resolves with extended TRT or requires additional therapeutic strategies.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.